RCAS1 Expression and Uterine Endometrial Cancer Outcomes
Author Information
Author(s): Sonoda K, Miyamoto S, Hirakawa T, Kaku T, Nakashima M, Watanabe T, Akazawa K, Fujita T, Nakano H
Primary Institution: Kyushu University
Hypothesis
The study aims to clarify the clinical prognostic significance of RCAS1 expression in uterine endometrial cancer.
Conclusion
RCAS1 overexpression is associated with poorer survival outcomes in patients with uterine endometrial cancer.
Supporting Evidence
- Patients with RCAS1 overexpression had a significantly poorer survival than those with normal or positive RCAS1 expression.
- The overall survival rates were 96% for normal expression, 78% for positive expression, and 40% for overexpression of RCAS1.
- Statistical analysis showed significant associations between RCAS1 overexpression and surgical stage, myometrial invasion, and peritoneal cytologic results.
Takeaway
This study found that a protein called RCAS1 can help predict how well patients with uterine cancer will do; more of this protein means a worse outcome.
Methodology
The study analyzed the association between RCAS1 expression and clinicopathologic variables in 147 patients with uterine endometrial cancer using immunohistochemistry and statistical analysis.
Limitations
The study may have limitations related to the retrospective nature and the specific patient population.
Participant Demographics
The mean age of participants was 54.3 years, with a range of 27–82 years.
Statistical Information
P-Value
<0.0001
Confidence Interval
3.990 – 16.816
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website